SCHEMBL31435504

SCHEMBL31435504

FC(F)C1CNCC1c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 9/20 0.43
KDM1A O60341 8/20 0.43
MAOB P27338 10/20 0.40
CCR5 P51681 1/20 0.40
GBA1 P04062 2/20 0.38
BACE1 P56817 1/20 0.38
CYP2C19 P33261 4/20 0.38
CYP2B6 P20813 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 2/20 0.38
LMNA P02545 2/20 0.38
TAAR1 Q96RJ0 2/20 0.38
CYP3A4 P08684 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
CYP2A6 P11509 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2C P28335 1/20 0.38
ADRA1A P35348 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL807454 0.81 MAOA (0.43) MAOAKDM1AMAOBCCR5GBA1
SCHEMBL17084189 0.81 MAOA (0.43) MAOAKDM1AMAOBCCR5GBA1
SCHEMBL15081932 0.81 MAOA (0.43) MAOAKDM1AMAOBCCR5GBA1
SCHEMBL17084154 0.81 MAOA (0.43) MAOAKDM1AMAOBCCR5GBA1
SCHEMBL8660684 0.79 MAOA (0.55) MAOAKDM1AMAOBCCR5BACE1
SCHEMBL3870077 0.79 MAOA (0.55) MAOAKDM1AMAOBCCR5BACE1
SCHEMBL3870080 0.79 MAOA (0.55) MAOAKDM1AMAOBCCR5BACE1
SCHEMBL1990780 0.75 MAOB (0.48) MAOAKDM1AMAOBCYP2C19CYP2B6
SCHEMBL12303430 0.72 MAPT (0.42) MAOAKDM1AMAOBCCR5BACE1
SCHEMBL12303435 0.72 MAPT (0.42) MAOAKDM1AMAOBCCR5BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179103-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS RECLUDIX PHARMA, INC. 2025-06-05 US disclosed
CN-119301127-A 6-Oxo-decahydro pyrrolo [1,2-a ] [1,5] diazocine and 6-oxo-decahydro-4H-pyrrolo [2,1-d ] [1,5] thiaazacine derivatives as modulators of STAT3 and STAT6 for the treatment of cancer and inflammatory conditions 瑞克鲁迪克斯制药股份有限公司 2025-01-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179103-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS STAT6, STAT3, STAT1 MAOA 4871/4885KDM1A 1183/4885MAOB 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.